B-type natriuretic peptide levels in obese patients with advanced heart failure.

[1]  J. Hollander,et al.  Relationship between obesity and B-type natriuretic peptide levels. , 2004, Archives of internal medicine.

[2]  T. Fukutomi,et al.  Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. , 2004, The American journal of cardiology.

[3]  J. Hollander,et al.  Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study , 2004 .

[4]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[5]  A. D. de Bold,et al.  Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. , 2004, Journal of molecular and cellular cardiology.

[6]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[7]  F. van Lente,et al.  Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.

[8]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[9]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[10]  P. McCullough,et al.  Sorting out the evidence on natriuretic peptides. , 2003, Reviews in cardiovascular medicine.

[11]  Heinrich Taegtmeyer,et al.  Obesity and the risk of heart failure. , 2002, The New England journal of medicine.

[12]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[13]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[14]  G. Fonarow,et al.  The relationship between obesity and mortality in patients with heart failure. , 2001, Journal of the American College of Cardiology.

[15]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[16]  Arya M. Sharma,et al.  The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension , 2001, Journal of Molecular Medicine.

[17]  K. Flegal,et al.  Criteria for definition of overweight in transition: background and recommendations for the United States. , 2000, The American journal of clinical nutrition.

[18]  F. Follath,et al.  Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. , 1999, American heart journal.

[19]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[20]  P. Dessı̀-Fulgheri,et al.  Expression of natriuretic peptide receptors in human adipose and other tissues , 1996, Journal of endocrinological investigation.

[21]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[22]  E. Anderson.  Hudson et al. , 1977 .